Sample Name
Sample Code
Sample Name
Sample Code
Sample Name
Sample Code
4
BIDU-SW
09888
5
JD HEALTH
06618
| (Q3)Sep 30, 2025 | (Q2)Jun 30, 2025 | (Q1)Mar 31, 2025 | (FY)Dec 31, 2024 | (Q4)Dec 31, 2024 | (Q3)Sep 30, 2024 | (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow (Indirect Method) | ||||||||||
| Cash flow from continuing operating activities | ||||||||||
| Net income from continuing operations | 7,949.01%56.67M | 2,460.92%54.27M | 261.07%15.21M | 35.26%-23.34M | -841.86%-16.72M | 28.00%704K | 113.23%2.12M | 49.79%-9.44M | -573.31%-36.05M | 61.00%-1.78M |
| Change in working capital | -3,449.37%-34M | 2,434.25%59.05M | -146.36%-845K | -31.37%105K | -421.95%-924K | -334.80%-958K | 510.21%2.33M | -1,419.23%-343K | 129.82%153K | 15.26%287K |
| -Change in receivables | ---- | 2,160.71%2.53M | -595.60%-2.53M | ---- | ---- | -39.86%252K | 119.02%112K | ---364K | ---- | ---- |
| -Change in other current assets | ---- | ---- | ---3K | ---- | ---- | ---- | ---- | --0 | ---- | ---- |
| -Change in other current liabilities | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cash from discontinued operating activities | ||||||||||
| Operating cash flow | -2,532.19%-34.67M | 2,812.81%58.66M | -105.02%-1.31M | -11.13%-1.21M | -2,654.35%-1.27M | -1,225.64%-1.32M | 330.17%2.01M | -125.44%-638K | 41.37%-1.09M | -58.62%-46K |
| Investing cash flow | ||||||||||
| Cash flow from continuing investing activities | ||||||||||
| Net investment purchase and sale | -990.10%-73.77M | -256.09%-104.97M | -147.80%-10.45M | -476.49%-73.48M | -765.85%-33.02M | -105.56%-6.77M | -1,053.82%-29.48M | -36.68%-4.22M | 44.66%-12.75M | -843.81%-3.81M |
| Cash from discontinued investing activities | ||||||||||
| Investing cash flow | -990.10%-73.77M | -256.09%-104.97M | -147.80%-10.45M | -476.49%-73.48M | -765.85%-33.02M | -105.56%-6.77M | -1,053.82%-29.48M | -36.68%-4.22M | 44.66%-12.75M | -843.81%-3.81M |
| Financing cash flow | ||||||||||
| Cash flow from continuing financing activities | ||||||||||
| Net commonstock issuance | 1,040.12%75.5M | 249.63%104.3M | 182.89%13.53M | 428.48%74.98M | 649.63%33.74M | 135.41%6.62M | 746.54%29.83M | 42.76%4.78M | -42.73%14.19M | 492.24%4.5M |
| Net other financing activities | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 | --0 |
| Cash from discontinued financing activities | ||||||||||
| Financing cash flow | 1,035.96%74.93M | 248.38%103.13M | 185.27%13.48M | 429.50%74.41M | 652.55%33.48M | 136.42%6.6M | 747.28%29.6M | 42.33%4.72M | -42.34%14.05M | 491.62%4.45M |
| Net cash flow | ||||||||||
| Beginning cash position | 2,163.46%58.85M | 338.74%2.03M | -47.64%311K | 58.40%594K | 27,700.00%1.11M | 568.38%2.6M | 42.15%462K | 58.40%594K | -57.96%375K | -92.86%4K |
| Current changes in cash | -2,151.68%-33.51M | 2,557.76%56.82M | 1,400.00%1.72M | -229.22%-283K | -235.76%-801K | -286.49%-1.49M | 3,240.63%2.14M | -164.00%-132K | 142.36%219K | 84.95%590K |
| End cash position | 2,179.23%25.35M | 2,163.46%58.85M | 338.74%2.03M | -47.64%311K | -47.64%311K | 27,700.00%1.11M | 568.38%2.6M | 42.15%462K | 58.40%594K | 58.40%594K |
| Free cash from | -2,532.19%-34.67M | 2,812.81%58.66M | -105.02%-1.31M | -11.13%-1.21M | -2,654.35%-1.27M | -1,225.64%-1.32M | 330.17%2.01M | -125.44%-638K | 41.37%-1.09M | -58.62%-46K |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | -- | Unqualified Opinion | -- | -- | -- | -- | Unqualified Opinion | -- |
FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.
Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.